CTLA4 and neoplasm: Recent years, with the understanding of tumor immune escape, multiple immune checkpoints have been identified for cancer immunotherapy therapy, including PD1/PD-L1, CTLA4, HLA-E/CD94-NKG2A, etc. (1–4).